Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck

Pierre Dodion, Franscesco Cognetti, Marc van Rymenant, Ottilia Dalesio, Anne Kirkpatrick, Marcel Rozencweig

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-six evaluable patients with locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck were treated with a combination of mitomycin (10 mg/m2 i.v. day 1), fluorouracil (500 mg/m2 i.v. days 1 + 8) and hydroxyurea (1 g/m2 orally days 2-14). Thirty-three patients had received prior radiation therapy and 34 prior chemotherapy. Only two patients exhibited a partial response. Hematological toxicity was substantial, with three patients experiencing leukopenia below 1000/mm3 and seven patients experiencing thrombocytopenia below 25,000/mm3. There were four cases of treatment-related bleeding and one infection. Other side-effects were mild to moderate. Low antitumor activity and substantial toxicity preclude further evaluation of this regimen in head and neck cancer.

Original languageEnglish
Pages (from-to)241-243
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number3
DOIs
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

Cite this